Vimarsana
Biggest News Aggregation in the World

Page 4 - Left Ventricular Dysfunction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Left Ventricular Dysfunction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Left Ventricular Dysfunction Today - Breaking & Trending Today

Signs of LV Injury Precede LV Dysfunction in OSA With Obesity - Vimarsana News

Signs of LV Injury Precede LV Dysfunction in OSA With Obesity

Myocardial strain imaging can show signs of injury before any onset of left ventricular dysfunction in patients with obstructive sleep apnea, especially those who are obese.

Left Ventricular Dysfunction Drugs in Development, 2022 Market Research Report: Pipeline Landscape, - Vimarsana News

Left Ventricular Dysfunction Drugs in Development, 2022 Market Research Report: Pipeline Landscape,

DUBLIN--(BUSINESS WIRE)--The "Left Ventricular Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.This pipeline guide provides comprehensive information on the therapeutics under development for Left Ven...

Could A.I. revolutionize the future of heart health? - Vimarsana News

Could A.I. revolutionize the future of heart health?

A.I. could address cardiovascular disease, which appears as the biggest health concern in the world, and offer new methods in the treatment of heart diseases.

Improved Heart Fibrosis, Functional Gains Linked in HFpEF Trial - Vimarsana News

Improved Heart Fibrosis, Functional Gains Linked in HFpEF Trial

But regression of myocardial fibrosis wasn't tied to the small LVEF improvement observed in the PIROUETTE trial of pirfenidone in patients with heart failure with preserved ejection fraction.

It's All Relative: How Much Dilated Cardiomyopathy Is Familial? - Vimarsana News

It's All Relative: How Much Dilated Cardiomyopathy Is Familial?

A large, multicenter cohort study supports phenotype-based screening of first-degree family members of patients with confirmed DCM without input, necessarily, from genetic testing.